EXTON, Pa., April 27 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq:VPHM - News) today announced that it has initiated an open-label, multi-dose Phase 2 study to evaluate the safety, and pharmacokinetics and pharmacodynamics of subcutaneous versus intravenous administration of Cinryze™ (C1 esterase inhibitor [human)] in 24 adolescents and adult subjects with hereditary angioedema (HAE). Cinryze was approved by the U.S. Food and Drug Administration in October 2008 for routine prophylaxis against angioedema attacks in adolescent and adult patients with HAE.
